Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Take-Home Messages: Immunotherapy for HNSCC

August 10th 2017

Practical Issues Surrounding Immunotherapy for HNSCC

August 10th 2017

Pseudoprogression on Immunotherapy in HNSCC

August 10th 2017

Immunotherapy for HNSCC

August 10th 2017

New Therapies for HNSCC

August 10th 2017

Refining Chemoradiation for Advanced HNSCC

August 10th 2017

The Role of Induction Chemotherapy in HNSCC

August 10th 2017

Surgery for Locally Advanced HNSCC

August 10th 2017

De-Escalation of Therapy for HPV-Positive HNSCC

August 10th 2017

Personalized Approaches to Head and Neck Cancer Therapy

August 10th 2017

Head and Neck Cancer and the AJCC 8th Edition

August 10th 2017

Genetic Landscape of HNSCC

August 10th 2017

Biology of Head and Neck Cancer

August 10th 2017

Expert Weighs in on PARP Inhibitor Advances in Ovarian Cancer

August 8th 2017

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Comprehensive Genomic Profiling May Identify Select Subsets in Ovarian Cancer

August 7th 2017

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.

Wakelee Shares Latest on Immunotherapy Agents, EGFR Inhibitors in Lung Cancer

August 4th 2017

Heather Wakelee, MD, discusses the latest developments with EGFR inhibitors and immunotherapy agents in non-small cell lung cancer.

Maintenance Olaparib Data Published as FDA Weighs Approval

August 1st 2017

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

Prostate Cancer: Advice for Oncologists on AR-V7 Testing

July 31st 2017

Experimental Strategies for AR-V7+ CRPC

July 31st 2017

Precision Medicine in mCRPC

July 31st 2017